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Summary 
Background. Chronic kidney disease is a common comorbidity in elderly patients with heart failure. Evidence 
supports the use of angiotensin inhibitors for patients with heart failure. However, there is little evidence with 
which to assess the risk and benefits of this treatment in elderly patients with renal dysfunction. 
Objective. To determine the efficacy and safety of angiotensin inhibitor reduction in patients with heart 
failure, chronic kidney disease and anaemia. 
Study design. Open randomized controlled clinical trial. 
Setting. Complexo Hospitalario Universitario A Coruña (Spain). 
Patients. Patients ≥ 50 years old, with heart failure, haemoglobin (Hb) < 12 mg/dl and creatinine clearance 
<60 ml/min/1.73 m2 admitted to hospital, in treatment with angiotensin inhibitors. Informed consent and 
Ethical Review Board approval were obtained. 
Intervention. A 50% reduction of angiotensin inhibitor dose of the basal treatment on admission (n = 30) in 
the intervention group. Control group (n = 16) with the standard basal dose. 
Main outcome measure. Primary outcome was difference in Hb (gr/dl), creatinine clearance (ml/min/1.73 m2) 
and protein C (mg/dl) between admission and 1–3 months after discharge. Secondary outcome was survival at 
6–12 months after discharge. 
Results. Patients in the intervention group experienced an improvement in Hb (10.62–11.47 g/dl), creatinine 
clearance (32.5 ml/min/1.73 m2 to 42.9 ml/min/1.73 m2), and a decrease in creatinine levels (1.98–
1.68 mg/dl) and protein C (3.23 mg/dl to 1.37 mg/dl). There were no significant differences in these variables 
in the control group. Survival at 6 and 12 months in the intervention and control group was 86.7% vs. 75% 
and 69.3% vs. 50%, respectively. 
Conclusion. The reduction of the dose of angiotensin inhibitors in the intervention group resulted in an 
improvement in anaemia and kidney function, decreased protein C and an increased survival rate.  
 
 
 
 
 
  
Introduction 
As a result of the progressive ageing of the population, heart failure and renal dysfunction 
frequently coexist in the same patient. Worsening renal function in patients with decompensated 
heart failure has an impact on short and long-term morbidity and mortality [1, 2] Gottlieb et al. [3] 
have shown that even a small increase in serum creatinine, for example 0.1 mg/dl, will worsen the 
outcome of these patients. 
 
Evidence-based treatment of heart failure is underused in patients with heart failure/chronic 
kidney disease because of concerns regarding the side effects of medication [1, 2, 4] Few 
prospective clinical trials have been carried out to define either the risk/benefit ratio of treatments 
in this population or to support dose adjustments [1], as a result of which little evidence is 
available to guide clinicians in the optimal management of patients with both conditions [5]. 
 
A wide range of complex pathophysiological interactions link the heart and kidney [3], and 
have been grouped under the term ‘cardiorenal syndrome’. A large number of patients are also 
affected by cardiorenal anaemia syndrome [6]. 
 
Anaemia is commonly found in patients with heart failure, regardless of the presence of renal 
parenchymal disease. The incidence of anaemia increased from 9% for patients with New York 
Heart Association (NYHA) class I to 79% for NYHA class IV, as reported by Silveberg [7]. Each 
1 g/dl decrease in serum haemoglobin was associated with increases in left ventricular dilatation 
and left ventricular hypertrophy, which in turn were associated with worsening renal function [8]. 
 
The mechanism of anaemia in chronic heart failure is almost certainly multifactorial. 
Congestion with renal sodium and water retention will lead to haemodilution [9, 10]. When 
worsening renal function occurs in heart failure patients, it may lead to relative erythropoietin 
deficiency [11, 12]. Inflammation and increased cytokine production occur with heart failure and 
can suppress erythrocytosis of the bone marrow [13, 14]. Iron and vitamin deficiency are also 
common and may contribute to anaemia [12]. Furthermore, angiotensin inhibitors cause a 
reduction in haemoglobin by decreasing erythropoietin [15] and by preventing the breakdown of 
the haematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline [16]. 
 
An analysis of the database of the Study of LV Dysfunction (SOLVD) by Al-Ahmad et al. [17] 
showed that for every 1% decrease in the haematocrit, the mortality rate increases by 2.7%. 
Moreover, a small number of studies in chronic heart failure patients have shown significant 
improvement in outcomes by increasing the haemoglobin level from 12 g/dl to 13 g/dl [7]. 
 
This study was carried out because of the lack of clinical trials in a vulnerable population of 
elderly patients with heart failure, chronic kidney disease and anaemia. 
 
The aim of this study was to determine the efficacy and safety of angiotensin inhibitors 
reduction in patients with heart failure, chronic kidney disease (creatinine clearance 
< 60 ml/min/1.73 m
2
) and anaemia (Hb < 12 mg/dl), by conducting an open randomized controlled 
clinical trial. 
 
The main goal of this study was to determine changes in haemoglobin and creatinine clearance 
after angiotensin inhibitor reduction. The secondary objective was to determine the probability of 
survival at 6 months and 1 year in the follow-up of this group of vulnerable patients. 
  
Methods 
Study design 
Open randomized controlled clinical trial. 
Setting 
Complexo Hospitalario Universitario A Coruña (Spain), with patients admitted to the Internal 
Medicine Service (A) in the period January–July 2009. 
Inclusion criteria 
Patients ≥ 50 years old, with chronic heart failure, Hb < 12 mg/dl and creatinine clearance 
< 60 ml/min/1.73 m
2
 admitted to hospital, with angiotensin inhibitors treatment. 
Exclusion criteria 
Heart failure because of acute myocardial ischaemia; patients requiring devices or surgery 
(revascularization, valvular replacement, pacemakers, implantable cardioverter-defibrillators 
(ICD), heart transplantation, ventricular assist devices, artificial heart); pericardial disease; acute 
bleeding; pulmonary embolism; patients being treated with erythropoietin, ultrafiltration, 
haemodialysis and oncology patients. 
Measurements 
The following variables were established for each of the patients included in the study: age, 
gender, body mass index, presence of diabetes, symptoms and signs in the diagnosis of heart 
failure, severity of heart failure according to The New York Heart Association classification 
(NYHA), time since the diagnosis of heart failure; electrocardiogram, chest X-ray, 
echocardiography as well as haematology and biochemistry tests were conducted (at admission 
and 1–3 months after discharge), in particular: complete blood count (haemoglobin, haematocrit, 
leucocytes, platelets), serum electrolytes, S-creatinine, S-uric acid, S-urea, S-glucose, S-insulin, S-
homocysteine, S-hepatic enzymes and urinalysis (proteinuria and glycosuria), Creatinine 
clearance, C-reactive protein (CRP), thyroid stimulating hormone (TSH). 
Intervention 
All of the patients with cardiac insufficiency received the treatment recommended in clinical 
practice guidelines [18] with respect to non-pharmacological and pharmacological therapy. 
 
The dose of renin-angiotensin system inhibitors taken by the patients in the intervention group 
on admission was reduced by 50%, while the control group continued to take the same dose of 
renin-angiotensin system inhibitors they were taking on admission. 
 
The initial treatment dose and the dose after the intervention with angiotensin-converting 
enzyme inhibitor and angiotensin receptor antagonists in both groups are shown in Tables 1 and 2. 
  
Table 1. Characteristics of patients included in the study by group 
 
Intervention group  Control group  
p 
n Mean ± SD  n Mean ± SD  
 
Age (years) 30 78.2 ± 7.8  17 74.2 ± 5.9  0.079 
BMI (weight/height2) 28 27.5 ± 4.9  15 29.1 ± 4.5  0.316 
Haemoglobin (g/dl) 30 10.6 ± 0.87  17 10.7 ± 1.02  0.735 
Haematocrit (%) 30 31.7 ± 2.65  17 32.16 ± 2.85  0.547 
Plasmatic creatinine (mg/dl) 30 1.97 ± 0.73  17 1.61 ± 0.36  0.068 
Creatinine clearance (24-h) (ml/min/1.73 m2) 30 31.97 ± 13.34  17 47.5 ± 8.74  <0.001 
Albuminury (mg/24 h) 28 0.39 ± 0.58  16 0.86 ± 1.23  0.130 
Ejection fraction (%) 29 48.20 ± 16.28  17 47.41 ± 11.7  0.862 
Time of heart failure diagnosis (years) 30 5.03 ± 3.95  17 4.29 ± 3.98  0.542 
Angiotensin inhibitors treatment at admission  
Angiotensin-converting-enzyme inhibitor (mg) (Enalapril) 18 8.3 ± 5.7  6 5.8 ± 2.0  0.494 
Angiotensin receptor antagonists (mg) (Losartan) 12 56.2 ± 35.6  11 52.3 ± 26.1  0.928 
  n  %   n  %   p  
Gender  
Male 16 59.3%  11 40.7%  
0.449 
Female 14 70.0%  6 30.0%  
NYHA Classification  
I 5 62.5%  3 37.5%  
0.736 
II 19 67.9%  9 32.1%  
III 6 54.5%  5 45.5%  
IV – –  – –  
Diabetes  
No 18 69.2%  8 30.8%  0.391 
Yes 12 57.1%  9 42.9%  
 
        
 
BMI, body mass index; NYHA, New York Heart Association Functional Classification; SD, standard deviation. 
 
Table 2. Changes in the parameters studied during follow-up in the treatment and control groups 
   
Intervention group   Control group  
Admission  1–3 months after discharge  
p  Relative change (%)  
 Admission  
1–3 months after 
discharge  
p  Relative change (%)  
Mean ± SD  Mean ± SD   Mean ± SD  Mean ± SD  
 
Haemoglobin (g/dl) 10.6 ± 0.9 11.5 ± 1.1 < 0.001 8%  10.6 ± 1.0 10.1 ± 1.6 0.198 −4.9% 
Haematocrit (%) 31.7 ± 2.8 34.4 ± 3.1 < 0.001 8.6%  32.0 ± 2.9 30.4 ± 4.7 0.212 −4.9% 
Plasmatic creatinine (mg/dl) 1.9 ± 0.7 1.7 ± 0.4 0.004 −15.1%  1.6 ± 0.4 1.5 ± 0.4 0.269 −6.3% 
Creatinine clearance (24-h) (ml/min/1.73 m2) 32.5 ± 13.9 42.9 ± 20.7 0.001 32%  48.3 ± 8.8 41.7 ± 11.9 0.056 −13.5% 
C-reactive protein (mg/dl) 3.2 ± 2.9 1.4 ± 1.9 0.008 −57.5%  1.9 ± 2.9 3.1 ± 5.9 0.560 6.2% 
Homocysteine (mmol/L) 23.4 ± 9.0 25.1 ± 17.7 0.454 7.6%  22.2 ± 5.4 17.9 ± 8.6 0.208 −19.20% 
Albuminury (mg/24 h) 0.43 ± 0.6 0.7 ± 1.2 0.231 5.9%  0.6 ± 0.9 0.7 ± 1.2 0.537 9.40% 
Insulin (mcU/ml) 13.4 ± 18.4 9.5 ± 3.9 0.286 −29%  12.3 ± 8.7 10.0 ± 10.8 0.132 18.40% 
  Admission  After randomization  p     Admission  After randomization  p    
Angiotensin-converting-enzyme inhibitor (mg) (Enalapril) 8.3 ± 5.7 4.2 ± 2.8 0.047    5.8 ± 2.0 5.8 ± 2.0 0.999   
Angiotensin receptor antagonists (mg) (Losartan) 56.2 ± 35.6 28.1 ± 17.8 0.008    52.3 ± 26.1 52.3 ± 26.1 0.999   
          
 
SD, standard deviation. 
 
Main outcome measure 
The main objective of this study was to determine changes in haemoglobin and creatinine 
clearance after angiotensin-inhibitor reduction in patients with heart failure, chronic kidney disease 
and anaemia. 
 
The efficacy was measured by haemoglobin and creatinine clearance assessment at admission 
and 1–3 months after discharge. 
 
Efficacy in terms of the pro-inflammatory variables was determined by measuring C protein, 
base insulin and homocysteine levels at admission and 1–3 months after discharge. 
 
All of the measurements were carried out in the same laboratory in the hospital. 
 
The secondary objective was to determine survival probability at 6 months and 1 year after 
admission in the patient follow-up. 
Sample size 
The literature points to a high prevalence of chronic renal insufficiency in patients with cardiac 
insufficiency, of around 40% [19]. In order to be included in our study, patients had to have renal 
insufficiency of at least grade III of the K/DOQ I (creatinine clearance < 60 ml/min/1.73 m
2
). If 
the treatment is expected to improve this renal insufficiency by 28% (100% vs. 72%), for a 
confidence of 95% and a statistical power of 80% we require 30 patients in the intervention group 
and 15 in the control group with a bilateral approach. The intervention group included twice as 
many patients as the control group, as a likely benefit was expected in the intervention group, and 
the aim was to minimise the lack of this benefit in the control group. 
 
If this sample size is considered for studying anaemia in patients, it can be affirmed that in 
order to detect a difference of 1.5 gr/dl (12 gr/dl vs. 10.5 gr/dl) with a standard deviation of 1.4 
(obtained from a sample of patients) for a confidence of 95% and a statistical power of 80%, 
assuming a 5% information loss with a bilateral approach, then the sample size required for each 
group would be 16 patients. In this study, there were 30 patients in the intervention group and 17 
in the control group. 
Randomization 
In order to balance the group sizes, a restricted randomization protocol was used [20]. Blocked 
randomization was used with a block size of six and an allocation ratio of 2 : 1 (four subjects to 
one group and two to the other), with a total of eight blocks. 
Blinding 
This was an open clinical trial. Only those assessing outcomes were blinded after assignment to 
interventions. 
Statistical methods 
Intention to treat (ITT) analysis was carried out, together with a descriptive study of the 
variables included in the study. The quantitative variables are expressed as the mean ± SD. The 
qualitative variables are expressed as an absolute value and percentage, with a 95% estimate of the 
confidence interval. To compare the characteristics of the different groups (treatment vs. control) 
Student's t-test or the Mann–Whitney test were used as appropriate. 
  
The association of qualitative variables was estimated using the χ2 test. After verifying 
normality with the Kolmogorov–Smirnov test, Student's paired t-test or the Wilcoxon test were 
used as applicable to compare the base values with the values after discharge. 
 
Actuarial survival analysis using Kaplan–Meier curves, the log-rank test and Cox's regression 
analysis were also carried out. 
 
Clinical relevance was estimated by calculating the Absolute Risk Reduction (ARR), the 
Relative Risk Reduction (RRR) between those who received treatment and those who did not, and 
the number needed to treat (NNT) in order to prevent death [21]. 
Ethics 
Informed consent of the patients and approval by Ethical Review Board were obtained (CEIC 
Code: 2008/327). European Clinical Trials database. EudraCT: 2008-008,480-10. 
Role of the funding source 
No funding. 
Results 
Table 1 shows the characteristics of the patients in the treatment and control groups. The 
patients were comparable in terms of age, BMI, base haemoglobin and haematocrit, albuminuria, 
ejection fraction and years of development of cardiac insufficiency. Furthermore, according to the 
NYHA classification there were no differences in terms of sex, dyspnoea or prevalence of 
diabetes. The patients in the intervention group had lower base creatinine clearance values than 
those in the control group; this difference was statistically significant. 
 
The doses of angiotensin-converting enzyme inhibitor (mg) (enalapril) and angiotensin 
receptor antagonists (losartan) at admission were similar in both groups (Table 2). 
 
The doses of angiotensin-converting enzyme inhibitor (mg) (enalapril) and angiotensin 
receptor antagonists (losartan) after randomization were statistically different in both groups 
(Table 2). 
 
After angiotensin inhibitor reduction, it was observed that in the intervention group there was a 
significant increase in the haemoglobin values (10.62–11.47 g/dl), haematocrit (31.7–34.4%) and 
creatinine clearance (32.5 ml/min/1.73 m
2
 to 42.9 ml/min/1.73 m
2
), and a significant decrease in 
the values for creatinine (1.98 mg/dl to 1.68 mg/dl) in serum and a decrease in protein C 
(3.23 mg/dl to 1.37 mg/dl). 
 
In the control group, there were no significant differences in any of the variables studied. In 
fact, certain adverse changes were observed, such as a decrease in haemoglobin, haematocrit and 
creatinine clearance values, and an increase in protein C values (Table 2). 
 
Table 2 shows the differences before and after the study in the control group and intervention 
group. It reveals significant divergences in the previously commented variables for haemoglobin, 
haematocrit, creatinine clearance and protein C. In the intervention group, there was an increase in 
haemoglobin, haematocrit and creatinine clearance, and a decrease in protein C values. However, 
in the control group, haemoglobin, haematocrit and creatinine clearance values decreased, with an 
increase in protein C values. 
 
In terms of the changes in relative size, it was observed that haemoglobin improved in the 
intervention group with respect to the base values by 8%, the haematocrit by 8.6%, and creatinine 
clearance by 32%. In turn, the values of C-reactive protein decreased by 57.7%. 
  
In the control group, these parameters not only failed to improve, but actually they worsened, 
with a reduction in the haemoglobin and haematocrit levels by 4.9%, a decrease in creatinine 
clearance of 13.5%, and an increase in protein C values of 6.22% (Table 2). 
 
A correlation was revealed between the reduced drug dose and the changes in the parameter 
values obtained before and after treatment. The more the doses of angiotensin receptor antagonists 
were reduced, the more the Hb improved (r = 0.314; p = 0.22), with creatinine clearance also 
improving significantly (r = 0.678; p = 0.003). 
 
After 3 months, the global survival rate was 97.9%, 80.9% after 6 months, and 60.8% after 
12 months. Taking individual results into consideration, it is evident that the survival rate was 
higher in the intervention group than in the control group (Figure 1). After 6 months it was 86.7% 
in the intervention group and 75% in the control group, while after 12 months it was 69.3% and 
50%, respectively. 
 
 
 
Figure 1. Survival probability by study group 
On adjusting a multivariate Cox's regression model for the variables treatment group, age, base 
creatinine clearance, base haemoglobin and ejection fraction, it is evident that the only variable 
that significantly modified the prognosis was the belonging to the intervention group (RR = 0.22) 
(Table 3). 
  
Table 3. Cox regression analysis to predict mortality in patients with heart failure adjusting for different covariables 
  B  SE  p  RR  95% CI (RR)  
Intervention group vs. control group −1.534 0.699 0.028 0.216 0.055 0.849 
Age (years) 0.080 0.060 0.186 1.083 0.962 1.219 
Creatinine clearance (24-h) (ml/min/1.73 m2) −0.038 0.027 0.150 0.963 0.914 1.014 
Haemoglobin (g/dl) 0.063 0.284 0.824 1.065 0.610 1.859 
Ejection fraction at admission (%) −0.025 0.017 0.152 0.975 0.942 1.009 
       
 
B, regression coefficient; SE, standard error; RR, relative risk; CI, confidence interval 
Table 4 shows the clinical relevance estimated on the basis of the ARR, RRR between those 
who received the intervention and those who did not, and the Number Needed to Treat (NNT) in 
order to prevent death at 6 and 12 months. The table also shows that the clinical impact increases 
over longer follow-up periods. The ARR at 6 and 12 months was 0.10 and 0.17 respectively; the 
Relative Risk Reduction was 0.46 at 6 months and 0.36 at 12 months, and the Number Needed to 
Treat (NNT) was 10 at 6 months, and 6 at 12 months. 
Table 4. Mortality rates in intervention and control groups, and indicators of clinical relevance 
  
Intervention 
group  
Control 
group  
ARR  RR  RRR  NNT  
. 
6-months 
mortality 
4/30 (13.3%) 4/17 (23.7%) 
10.2% (−13.4%; 
33.7%) 
0.57 (0.16; 
1.98) 
43.3% (−98.1%; 
83.8%) 
10 (−8;3) 
12-months 
mortality 
9/30 (30.0%) 8/17 (47.1%) 17.1% (−11.8; 45.9) 
0.64 (0.30; 
1.64) 
36.3% (−34.1%; 
69.7%) 
6 (−9;3) 
       
 
ARR, Absolute Risk Reduction; RR, relative risk; RRR, Relative Risk Reduction; NNT, number needed to treat 
Discussion 
The patients with cardiac insufficiency who took part in this study and met the inclusion 
criteria for anaemia (Hb < 12 mg/dl) and creatinine clearance (<60 ml/min/1.73 m
2
) were similar 
in terms of the prevalence of diabetes, hypertension, chronic obstructive pulmonary disease and 
ischaemic cardiopathy to those included in other studies of patients with anaemia and cardiac 
insufficiency. [22-24]. 
 
Of the total patients, 97% of the patients were given angiotensin inhibitors, 80% were given 
diuretics, 55% beta-blockers and 21% calcium antagonists. Treatment with angiotensin inhibitors 
in this series is higher than that in other publications (GESAIC – 56%, Nanas – 56.8%) [22, 23]. 
 
In this study, anaemia corresponded to the chronic disorder pattern in 48.98% of the cases, 
followed by iron-deficiency anaemia in 27.6%, which bears similarity to other series [23-25]. 
  
Efficacy of the reduction of angiotensin inhibitors in anaemia treatment 
The renin-angiotensin system appears to be closely involved in the control of erythropoiesis. 
Angiotensin II decreases pO2 by reducing renal blood flow, and stimulates erythropoietin 
production. Angiotensin II also directly stimulates bone marrow erythroid progenitor cells [15, 16, 
26, 27]. 
 
The results obtained show that anaemia improves by reducing the dose of angiotensin 
inhibitors in patients with cardiac and renal insufficiency, and are consistent with the 
physiopathological mechanisms commented above and with other studies[15, 16, 28] that refer to 
the role these drugs play in causing anaemia. 
 
In the SOLVD [28] study, the incidence of anaemia after 1 year of follow-up was 11.3% with 
enalapril, and 7.9% for the placebo group. The patients who developed de novo anaemia had a 
global mortality rate increased by 108%, and in the multivariate analysis, a decrease of one point 
in the haematocrit was associated with an RR of 1.027 for mortality. 
 
In the GESAIC [22] study, the variable with the highest risk associated with chronic anaemia 
was the angiotensin inhibitors (OR = 3.29; 95% CI: 1.36–7.94). 
 
When we compare the values from before treatment with those from after treatment in our 
clinical study, the reduction of angiotensin inhibitors led to a significant increase in the values of 
haemoglobin (10.62–11.47 g/dl) and haematocrit (31.7–34.4%). 
 
In the control group, there were no differences in any of the variables that were studied; in fact, 
a decrease in the haemoglobin and haematocrit values was observed. 
Efficacy of the reduction of angiotensin inhibitors in renal function improvement 
In this study, the patients in the intervention group presented a clear improvement in creatinine 
clearance, from 32.5 ml/min/1.73 m
2
 to 42.9 ml/min/1.73 m
2
 and a significant decrease in their 
creatinine values from 1.98 mg/dl to 1.68 mg/dl, with a higher survival rate than the control group. 
There were no significant differences in any of the variables studied in the control group, and in 
fact, a decrease in the creatinine clearance values was revealed. Moreover, the more the dose of 
angiotensin receptor blockers was reduced, the greater the improvement in the Hb (r = 0.314; 
p = 0.22) was observed, with a significant creatinine clearance (r = 0.678; p = 0.003). 
 
The Cooperative North Scandinavian Enalapril Survival Study [29] showed that 20–30% of 
patients presented reduced glomerular filtration rate after the introduction of enalapril. 
 
In the CHARM [30] study, a correlation was revealed between different creatinine clearance 
levels and mortality. 
Results in terms of survival 
This study showed that after adjusting a Cox's regression analysis for the variables assigned 
group, patient age, creatinine clearance, haemoglobin and ejection fraction, the variable with an 
independent effect in predicting mortality was the intervention group (RR = 0.22). 
 
After reducing the dose of angiotensin inhibitors, the risk of death was reduced by 43% with 
respect to the control group. 
 
Felker et al. [31]. indicated an increase in the mortality rate of 3% for each one point decrease 
in the haematocrit. 
 
The clinical relevance of this intervention is indicated by the Relative Risk Reduction 
(RRR = 0.43) and Number Needed to Treat (NNT = 10) after 6 and 12 months of follow-up 
(RRR = 0.36, NNT = 6) (Table 4).  
In terms of the limitations of the study, it should be mentioned that although it was 
randomized, it was an open study. Blinding was not maintained neither for the clinician carrying 
out the intervention nor for the patient, as the study formed a part of the normal clinical practice in 
treating these patients. 
 
This may have led to an information bias, although the response variables that comprised 
analytical and survival findings were entered into a database as anonymous data by people who 
were not directly involved in the study. 
 
Follow-up was carried out in a similar way with both groups, so that surveillance bias, a type 
of non-random misclassification bias, is not applicable in the intervention group nor in the control 
group. All of the patients were examined with the same frequency and at the same intervals, with 
the same analytical findings during follow-up. 
 
Although the groups were randomized, they were comparable in the majority of the variables 
of interest. However, the intervention group initially had lower creatinine clearance values than the 
control group. This difference was taken into account when adjusting the Cox's regression models. 
Even so, these values improved after intervention, and were higher than those of the control group. 
 
Despite having a small sample size, statistically significant differences were found in the 
parameters of interest. This study has a statistical power of 80% and a confidence of 95% for 
detecting differences of at least 28% in the improvement of renal function, and the ability to detect 
a difference of 1.5 gr/dl in haemoglobin with the same confidence and statistical power. 
 
The main objective of the study was not to determine the survival rate or prognostic factors of 
the patients after treatment, and the sample size was not calculated for this purpose, but instead the 
intention was to evaluate the incidence of anaemia and renal function after treatment. Despite not 
being a main objective, the survival rate was studied during the follow-up. For this reason, 
although there are differences in the mortality rate in the univariate analysis, the effect is not 
significant. In any event, after adjusting for the variables of interest, it was found in the regression 
model that belonging to the intervention group had an independent and statistically significant 
effect on reducing mortality. 
Contributions of the study 
This study clearly demonstrates the positive effect of reducing medication on the parameters 
that were studied. Significant differences were found in the reduction of anaemia, improvement of 
renal function and improvements in pro-inflammatory markers. After adjusting for the prognostic 
variables of interest, it was found that belonging to the intervention group was effective for 
improving anaemia, improving renal function and increased survival. It was also ascertained that 
the amount by which angiotensin-inhibiting drugs were reduced was related with the degree of 
improvement, which supports the hypothesis of a causal and dose-dependent relationship. 
 
Our results are in line with the recommendations of the ACCF/AHA Guidelines for the 
Diagnosis and Management of Heart Failure in Adults [18], which state that worsening renal 
function may require adjustment of the doses of renin-angiotensin-aldosterone system antagonists. 
 
Few authors have pointed to the importance of reducing the dose of angiotensin inhibitors in 
this subgroup of patients, as there is little evidence of the risks and benefits of these drugs in 
elderly patients [4]. 
 
These findings must be verified by subsequent studies, and if the results are found to be 
consistent, this will prove that reducing the drug dose, taking renal function into account, may 
have a clearly beneficial and clinically relevant effect for this group of patients. 
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